Wikidata entity: Q63573558
Quantities
| P2899 | minimum age | 50 |
| P1132 | number of participants | 500 |
| P6099 | clinical trial phase | ... | Q42824827 (phase III clinical trial) | phase III clinical trial |
| P17 | country | ... | Q30 (United States) | United States |
| P582 | end time | ... | 2020-01-10 | ??? |
| P31 | instance of | ... | Q30612 (clinical trial) | clinical trial |
| P921 | main subject | ... | Q55011690 (Clostridium difficile intestinal infectious disease) | Clostridium difficile intestinal infectious disease |
| P921 | main subject | ... | Q310543 (Clostridium difficile) | Clostridium difficile |
| P6153 | research site | ... | Q30270351 (Progressive Clinical Research) | Progressive Clinical Research |
| P6153 | research site | ... | Q30269657 (Coastal Carolina Research Center) | Coastal Carolina Research Center |
| P6153 | research site | ... | Q30270033 (PMG Research) | PMG Research |
| P6153 | research site | ... | Q30270096 (Martin Diagnostic Clinic) | Martin Diagnostic Clinic |
| P6153 | research site | ... | Q30270193 (Meridian Clinical Research) | Meridian Clinical Research |
| P859 | sponsor | ... | Q206921 (Pfizer) | Pfizer |
| P580 | start time | ... | 2019-04-01 | ??? |
| P8363 | study type | ... | Q78089383 (interventional study) | interventional study |
| P1476 | title | Monolingualtext | A PHASE 3, RANDOMIZED OBSERVER-BLINDED STUDY TO EVALUATE THE IMMUNOGENICITY, SAFETY, AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | ??? |
| P3098 | ClinicalTrials.gov ID | NCT03918629 |
Why not click here or view trends?
log id: 5672692